Monoclonal antibody 75% effective in infants against respiratory viral infection
Pharmaceutical Journal
; 308(7959), 2022.
Article
in English
| EMBASE | ID: covidwho-2065023
Keywords
nirsevimab; palivizumab; placebo; article; coronavirus disease 2019; drug cost; drug dose regimen; hospitalized infant; human; infant; infection prevention; lower respiratory tract infection; monoclonal antibody therapy; phase 3 clinical trial (topic); respiratory syncytial virus infection; single drug dose; unspecified side effect
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Experimental Studies
Language:
English
Journal:
Pharmaceutical Journal
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS